HLA class I antigen defects in malignant cells - functional and clinical relevance

Published on June 30, 2015   23 min

Other Talks in the Series: Immunotherapy of Cancer

0:00
I am Soldano Ferrone, I hold the faculty position at the Massachusetts General Hospital, Harvard Medical School, in Boston, Massachusetts, United States. My research interest is in the area of tumor immunology. And especially in the mechanisms, which are utilized by tumor cells in order to escape recognition and destruction
0:27
by the host immune system. Over the years, I have investigated how tumor cells change in the expression of HLA class I and class II antigens, and how these changes have an impact on the direction of tumor cells with host immune systems. And as a result on the clinical course of the disease, and on the response to immunotherapeutic strategies. Now today sounds right to discuss with you the changes which have been identified in the expression and function of HLA class I antigen processing machinery in malignant cells. And as you know, in man, like in other animal species when cells undergo malignant transformation
Hide

HLA class I antigen defects in malignant cells - functional and clinical relevance

Embed in course/own notes